NovoCure Ltd. (NVCR)
International Markets and NovoCure (NVCR): A Deep Dive for Investors
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer
NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase 2 PANOVA-4 trial in 1st-line metastatic pancreatic cancer; topline data is expected in Q1 2026. Full-year 2025 revenues grew 8% year-over-year to $655.4 million, supported by 4,620 active TTFields patients globally and strong U.S. sales momentum.
What's Happening With NovoCure Stock?
NovoCure stock (NVCR) is up over 30% following the FDA's approval of its Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment in almost 30 years.
Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
The Swiss biopharmaceutical company's shares surged in after-hours trading after it said the FDA approved its Optune Pax product.
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy
Despite an expected 7% revenue growth for FY2025, NVCR stock price was cut in half in 2025 following the disappointing adoption of Optune Lua in the US and Germany. Yet, the company pipeline has multiple shots on goal which could materially improve its revenue growth trajectory and profitability as early as 2027. Most key approvals and data readouts are expected in 2026, representing potential catalysts for a strong rebound.
